



MS155-ED-X

Li Fraumeni Syndrome: Genomics, Oncogenesis and Where to Look on Whole-Body Surveillance Imaging

All Day Room: MS Community, Learning Center Digital Education Exhibit

Awards

Certificate of Merit

Participants

Nikita Consul, MD, Houston, TX (*Presenter*) Nothing to Disclose
Katherine J. Blair, MD, Houston, TX (*Abstract Co-Author*) Nothing to Disclose
Behrang Amini, MD, PhD, Houston, TX (*Abstract Co-Author*) Nothing to Disclose
Dhakshina M. Ganeshan, FRCP, MBBS, Houston, TX (*Abstract Co-Author*) Nothing to Disclose
Komal B. Shah, MD, Houston, TX (*Abstract Co-Author*) Nothing to Disclose
Tanya W. Moseley, MD, Houston, TX (*Abstract Co-Author*) Consultant, Hologic, Inc
Khaled M. Elsayes, MD, Pearland, TX (*Abstract Co-Author*) Nothing to Disclose

For information about this presentation, contact:

kmelsayes@mdanderson.org

TEACHING POINTS

1. Review the genomics, oncogenesis and epidemiology of Li Fraumeni Syndrome (LFS). 2. Discuss the various tumor presentations of LFS 3. Illustrate the spectrum of associations and imaging features of associated malignancies. 4. Describe the utility, eligibility criteria and usefulness of whole-body surveillance.

TABLE OF CONTENTS/OUTLINE

a. Epidemiology of LFSi. Age/genderii. Geographic distribution, populations at riskiii. Pattern of inheritance, discovery by Li and Fraumeni in 1969b. Pathophysiology of LFSi. Genomicsii. Oncogenesisiii. Emphasis on susceptible types of tissues/organsc. Surveillance imaging techniquesd. Specific imaging examples of associated cancers that can be seen with surveillancee. Breast cancerii. Adrenocortical carcinomaiii. Choroid plexus carcinomaii. Soft tissue sarcoma, especially rhabdomyosarcomavi. Early onset melanomavi. Multiple otherse. Recommendations regarding management and genetic counseling

Printed on: 01/18/21